Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Exercise | 142 | 2023 | 5788 | 7.750 |
Why?
|
Physical Fitness | 37 | 2021 | 732 | 3.760 |
Why?
|
Motor Activity | 28 | 2022 | 2685 | 3.140 |
Why?
|
Risk Reduction Behavior | 20 | 2022 | 1098 | 2.480 |
Why?
|
Mortality | 31 | 2021 | 2886 | 2.250 |
Why?
|
Fatty Acids, Omega-3 | 23 | 2023 | 1373 | 2.210 |
Why?
|
Walking | 20 | 2022 | 1188 | 2.200 |
Why?
|
Women's Health | 32 | 2023 | 2057 | 2.120 |
Why?
|
Cardiovascular Diseases | 61 | 2023 | 15399 | 1.910 |
Why?
|
Cholecalciferol | 17 | 2023 | 549 | 1.820 |
Why?
|
Coronary Disease | 24 | 2022 | 5917 | 1.740 |
Why?
|
Leisure Activities | 11 | 2022 | 306 | 1.730 |
Why?
|
Dietary Supplements | 42 | 2023 | 3387 | 1.670 |
Why?
|
Body Mass Index | 72 | 2022 | 12876 | 1.610 |
Why?
|
Resistance Training | 7 | 2018 | 185 | 1.490 |
Why?
|
Vitamin D | 36 | 2023 | 3283 | 1.260 |
Why?
|
Longevity | 13 | 2021 | 1050 | 1.190 |
Why?
|
Weight Gain | 11 | 2022 | 2346 | 1.180 |
Why?
|
Risk Factors | 182 | 2023 | 73809 | 1.170 |
Why?
|
Prospective Studies | 152 | 2023 | 54137 | 1.160 |
Why?
|
Vitamins | 20 | 2023 | 1632 | 1.100 |
Why?
|
Diabetes Mellitus, Type 2 | 32 | 2022 | 12075 | 1.080 |
Why?
|
Middle Aged | 277 | 2023 | 219568 | 1.040 |
Why?
|
Health Promotion | 16 | 2022 | 2204 | 0.980 |
Why?
|
Aged | 208 | 2023 | 168218 | 0.960 |
Why?
|
Proportional Hazards Models | 68 | 2022 | 12440 | 0.940 |
Why?
|
Neoplasms | 42 | 2023 | 22032 | 0.910 |
Why?
|
Obesity | 37 | 2023 | 12870 | 0.900 |
Why?
|
Health Behavior | 15 | 2018 | 2617 | 0.860 |
Why?
|
Female | 273 | 2023 | 390323 | 0.840 |
Why?
|
Overweight | 16 | 2023 | 2411 | 0.820 |
Why?
|
Humans | 403 | 2023 | 758406 | 0.820 |
Why?
|
Public Health | 11 | 2020 | 2658 | 0.810 |
Why?
|
Incidence | 79 | 2023 | 21272 | 0.790 |
Why?
|
Smoking | 39 | 2021 | 9051 | 0.790 |
Why?
|
Colorectal Neoplasms | 32 | 2022 | 6852 | 0.770 |
Why?
|
Actigraphy | 6 | 2019 | 518 | 0.740 |
Why?
|
Life Style | 21 | 2022 | 3886 | 0.690 |
Why?
|
C-Reactive Protein | 18 | 2022 | 3812 | 0.670 |
Why?
|
Vitamin B 6 | 6 | 2019 | 233 | 0.640 |
Why?
|
Follow-Up Studies | 81 | 2022 | 39059 | 0.620 |
Why?
|
Cohort Studies | 85 | 2023 | 41256 | 0.620 |
Why?
|
Cholangiocarcinoma | 6 | 2020 | 550 | 0.610 |
Why?
|
Bile Duct Neoplasms | 6 | 2019 | 602 | 0.610 |
Why?
|
Breast Neoplasms | 32 | 2023 | 21017 | 0.610 |
Why?
|
Male | 201 | 2023 | 358747 | 0.590 |
Why?
|
Dyslipidemias | 3 | 2015 | 867 | 0.580 |
Why?
|
Photoperiod | 1 | 2018 | 139 | 0.580 |
Why?
|
Vitamin E | 9 | 2012 | 870 | 0.570 |
Why?
|
Life Expectancy | 5 | 2015 | 1244 | 0.530 |
Why?
|
Energy Metabolism | 14 | 2019 | 2868 | 0.530 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 6 | 2023 | 3227 | 0.530 |
Why?
|
Ovarian Neoplasms | 13 | 2022 | 4876 | 0.520 |
Why?
|
Colonic Neoplasms | 7 | 2021 | 2523 | 0.520 |
Why?
|
Risk | 36 | 2021 | 9599 | 0.520 |
Why?
|
Alcohol Drinking | 18 | 2019 | 4018 | 0.510 |
Why?
|
Pancreatic Neoplasms | 13 | 2021 | 5349 | 0.510 |
Why?
|
Adult | 155 | 2022 | 219935 | 0.510 |
Why?
|
Aspirin | 18 | 2013 | 3131 | 0.500 |
Why?
|
United States | 84 | 2021 | 72136 | 0.500 |
Why?
|
Diet | 18 | 2021 | 8005 | 0.500 |
Why?
|
Time Factors | 33 | 2020 | 39872 | 0.490 |
Why?
|
Cause of Death | 12 | 2018 | 3675 | 0.490 |
Why?
|
Double-Blind Method | 35 | 2022 | 12262 | 0.490 |
Why?
|
Arthritis, Rheumatoid | 7 | 2023 | 3755 | 0.460 |
Why?
|
Eggs | 2 | 2021 | 183 | 0.460 |
Why?
|
Television | 3 | 2019 | 409 | 0.440 |
Why?
|
Antioxidants | 3 | 2008 | 1662 | 0.440 |
Why?
|
Video Games | 3 | 2020 | 191 | 0.440 |
Why?
|
Japan | 18 | 2020 | 1366 | 0.430 |
Why?
|
Cost of Illness | 2 | 2013 | 1936 | 0.420 |
Why?
|
Liver Neoplasms | 9 | 2021 | 4313 | 0.420 |
Why?
|
Body Weight | 9 | 2020 | 4603 | 0.420 |
Why?
|
Inflammation | 14 | 2022 | 10718 | 0.410 |
Why?
|
Risk Assessment | 34 | 2020 | 23884 | 0.400 |
Why?
|
Case-Control Studies | 45 | 2021 | 22029 | 0.390 |
Why?
|
Amino Acids, Branched-Chain | 4 | 2022 | 263 | 0.390 |
Why?
|
Connective Tissue Diseases | 4 | 2010 | 285 | 0.390 |
Why?
|
Dairy Products | 4 | 2016 | 491 | 0.390 |
Why?
|
Stroke | 12 | 2020 | 9694 | 0.390 |
Why?
|
alpha-Tocopherol | 2 | 2017 | 126 | 0.380 |
Why?
|
Vitamin D Deficiency | 5 | 2023 | 1377 | 0.380 |
Why?
|
Aged, 80 and over | 63 | 2021 | 58683 | 0.380 |
Why?
|
Sex Factors | 14 | 2022 | 10504 | 0.380 |
Why?
|
Adiposity | 6 | 2022 | 1858 | 0.370 |
Why?
|
Contraceptives, Oral | 2 | 2019 | 554 | 0.370 |
Why?
|
beta Carotene | 3 | 2002 | 523 | 0.370 |
Why?
|
Breast Implants | 4 | 2010 | 409 | 0.370 |
Why?
|
Multivariate Analysis | 24 | 2020 | 12096 | 0.370 |
Why?
|
Muscle Strength | 4 | 2020 | 618 | 0.360 |
Why?
|
Postmenopause | 14 | 2023 | 2509 | 0.360 |
Why?
|
Myocardial Infarction | 10 | 2023 | 11424 | 0.360 |
Why?
|
Geriatric Assessment | 1 | 2018 | 1404 | 0.350 |
Why?
|
Prostatic Neoplasms | 14 | 2019 | 11336 | 0.350 |
Why?
|
Hearing Loss | 3 | 2022 | 780 | 0.340 |
Why?
|
Lung Neoplasms | 16 | 2021 | 13245 | 0.330 |
Why?
|
Age Factors | 24 | 2021 | 18358 | 0.330 |
Why?
|
Polymorphism, Single Nucleotide | 15 | 2021 | 15773 | 0.330 |
Why?
|
Anticarcinogenic Agents | 2 | 2012 | 249 | 0.320 |
Why?
|
Diabetes Mellitus | 7 | 2020 | 5816 | 0.320 |
Why?
|
Sports | 8 | 2016 | 699 | 0.320 |
Why?
|
Chronic Disease | 8 | 2020 | 9267 | 0.320 |
Why?
|
Fatty Acids, Omega-6 | 2 | 2020 | 226 | 0.320 |
Why?
|
Cholesterol, HDL | 5 | 2022 | 1808 | 0.310 |
Why?
|
Carcinoma, Hepatocellular | 5 | 2020 | 2292 | 0.310 |
Why?
|
Carcinoma, Large Cell | 2 | 2019 | 113 | 0.310 |
Why?
|
Carcinoma, Pancreatic Ductal | 4 | 2021 | 1724 | 0.310 |
Why?
|
Cholesterol, Dietary | 1 | 2008 | 223 | 0.310 |
Why?
|
Self Report | 5 | 2020 | 3714 | 0.300 |
Why?
|
Sex Hormone-Binding Globulin | 3 | 2020 | 546 | 0.300 |
Why?
|
Policy | 3 | 2022 | 511 | 0.300 |
Why?
|
Calcium, Dietary | 3 | 2016 | 529 | 0.300 |
Why?
|
Monitoring, Physiologic | 1 | 2015 | 1780 | 0.300 |
Why?
|
Primary Prevention | 8 | 2020 | 1185 | 0.300 |
Why?
|
Biliary Tract Neoplasms | 2 | 2020 | 184 | 0.300 |
Why?
|
Randomized Controlled Trials as Topic | 22 | 2020 | 10146 | 0.300 |
Why?
|
Reproductive History | 2 | 2020 | 211 | 0.290 |
Why?
|
Urinary Incontinence | 2 | 2022 | 495 | 0.290 |
Why?
|
Vitamin B 12 | 4 | 2019 | 522 | 0.290 |
Why?
|
Adenoma | 4 | 2020 | 2148 | 0.290 |
Why?
|
Fishes | 1 | 2010 | 601 | 0.290 |
Why?
|
Aging | 6 | 2021 | 8650 | 0.270 |
Why?
|
Eicosapentaenoic Acid | 4 | 2023 | 560 | 0.270 |
Why?
|
Interleukin-6 | 6 | 2020 | 3208 | 0.270 |
Why?
|
Waist Circumference | 6 | 2022 | 921 | 0.270 |
Why?
|
Health Surveys | 15 | 2018 | 4064 | 0.270 |
Why?
|
Weight Loss | 5 | 2020 | 2671 | 0.260 |
Why?
|
Estrogens, Conjugated (USP) | 2 | 2006 | 275 | 0.260 |
Why?
|
Guidelines as Topic | 3 | 2019 | 1386 | 0.260 |
Why?
|
Folic Acid | 5 | 2018 | 1309 | 0.260 |
Why?
|
Insulin-Like Growth Factor I | 5 | 2017 | 1927 | 0.260 |
Why?
|
Survivors | 2 | 2014 | 2370 | 0.250 |
Why?
|
Ovary | 2 | 2020 | 958 | 0.250 |
Why?
|
Colonic Polyps | 2 | 2020 | 551 | 0.240 |
Why?
|
Occupational Health | 3 | 2020 | 805 | 0.240 |
Why?
|
Anthropometry | 3 | 2019 | 1347 | 0.240 |
Why?
|
Flavonoids | 2 | 2009 | 443 | 0.240 |
Why?
|
Diet, Mediterranean | 2 | 2022 | 736 | 0.240 |
Why?
|
Epidemiology | 2 | 2010 | 279 | 0.240 |
Why?
|
Cerebrovascular Disorders | 4 | 1999 | 1475 | 0.230 |
Why?
|
Attitude to Health | 3 | 2012 | 2026 | 0.230 |
Why?
|
Energy Intake | 6 | 2016 | 2127 | 0.230 |
Why?
|
Fish Oils | 4 | 2023 | 481 | 0.230 |
Why?
|
Menopause | 6 | 2020 | 1639 | 0.230 |
Why?
|
Hypertension | 13 | 2020 | 8499 | 0.230 |
Why?
|
Bile Ducts, Intrahepatic | 4 | 2020 | 296 | 0.230 |
Why?
|
Blood Pressure | 11 | 2019 | 8451 | 0.220 |
Why?
|
Docosahexaenoic Acids | 4 | 2023 | 905 | 0.220 |
Why?
|
Confidence Intervals | 9 | 2019 | 2925 | 0.220 |
Why?
|
Gonadal Steroid Hormones | 4 | 2020 | 701 | 0.220 |
Why?
|
Genome-Wide Association Study | 10 | 2022 | 12604 | 0.220 |
Why?
|
Environment | 1 | 2009 | 1118 | 0.220 |
Why?
|
Affect | 2 | 2021 | 1480 | 0.220 |
Why?
|
Physicians | 11 | 2011 | 4580 | 0.210 |
Why?
|
Nurses | 3 | 2022 | 2467 | 0.210 |
Why?
|
Carcinoma, Renal Cell | 4 | 2019 | 3217 | 0.210 |
Why?
|
Parkinson Disease | 2 | 2007 | 2862 | 0.210 |
Why?
|
Glycoproteins | 3 | 2016 | 2205 | 0.210 |
Why?
|
Genetic Predisposition to Disease | 13 | 2021 | 17768 | 0.210 |
Why?
|
Menarche | 2 | 2021 | 529 | 0.210 |
Why?
|
Neoplasms, Glandular and Epithelial | 2 | 2017 | 487 | 0.200 |
Why?
|
Receptors, Tumor Necrosis Factor, Type II | 3 | 2019 | 346 | 0.200 |
Why?
|
Mendelian Randomization Analysis | 4 | 2020 | 993 | 0.200 |
Why?
|
Lipid Metabolism | 2 | 2021 | 1895 | 0.200 |
Why?
|
Odds Ratio | 16 | 2019 | 9650 | 0.200 |
Why?
|
Scotland | 3 | 2018 | 143 | 0.200 |
Why?
|
Adiponectin | 3 | 2015 | 1114 | 0.200 |
Why?
|
Tea | 1 | 2003 | 284 | 0.190 |
Why?
|
Epidemiologic Factors | 1 | 2001 | 36 | 0.190 |
Why?
|
Urban Population | 1 | 2009 | 2025 | 0.190 |
Why?
|
Endometrial Neoplasms | 2 | 2021 | 1357 | 0.190 |
Why?
|
Kidney Neoplasms | 4 | 2019 | 4312 | 0.190 |
Why?
|
Cotinine | 2 | 2018 | 203 | 0.190 |
Why?
|
Physical Exertion | 6 | 2019 | 662 | 0.190 |
Why?
|
Receptors, Estrogen | 5 | 2020 | 2210 | 0.190 |
Why?
|
Urinary Bladder, Overactive | 1 | 2022 | 114 | 0.180 |
Why?
|
Knee Joint | 2 | 2020 | 1663 | 0.180 |
Why?
|
Body Constitution | 1 | 2001 | 273 | 0.180 |
Why?
|
Logistic Models | 17 | 2022 | 13276 | 0.180 |
Why?
|
Intercellular Adhesion Molecule-1 | 4 | 2020 | 1125 | 0.180 |
Why?
|
England | 3 | 2018 | 524 | 0.180 |
Why?
|
Anti-Inflammatory Agents | 1 | 2010 | 1793 | 0.180 |
Why?
|
Metabolic Equivalent | 1 | 2019 | 14 | 0.180 |
Why?
|
Kynurenine | 2 | 2019 | 139 | 0.180 |
Why?
|
Glucose Metabolism Disorders | 1 | 2020 | 52 | 0.180 |
Why?
|
Androgens | 3 | 2017 | 1291 | 0.170 |
Why?
|
Proteins | 3 | 2018 | 6026 | 0.170 |
Why?
|
Respiratory Physiological Phenomena | 3 | 2010 | 188 | 0.170 |
Why?
|
Chromosomes, Human, Pair 2 | 1 | 2021 | 313 | 0.170 |
Why?
|
Polysaccharides | 2 | 2016 | 1007 | 0.170 |
Why?
|
Acinetobacter baumannii | 1 | 2021 | 115 | 0.170 |
Why?
|
Insulin Resistance | 5 | 2021 | 3941 | 0.170 |
Why?
|
Longitudinal Studies | 14 | 2020 | 14490 | 0.170 |
Why?
|
Cardiovascular Physiological Phenomena | 3 | 2011 | 239 | 0.170 |
Why?
|
Parity | 2 | 2019 | 925 | 0.170 |
Why?
|
Cholesterol, LDL | 4 | 2022 | 2374 | 0.160 |
Why?
|
Prolactin | 1 | 2021 | 621 | 0.160 |
Why?
|
Health Status | 7 | 2019 | 4071 | 0.160 |
Why?
|
Depressive Disorder | 3 | 2021 | 3727 | 0.160 |
Why?
|
Population Surveillance | 4 | 2018 | 2606 | 0.160 |
Why?
|
Ovulation | 1 | 2020 | 181 | 0.160 |
Why?
|
Candy | 1 | 1998 | 36 | 0.160 |
Why?
|
Hyperglycemia | 2 | 2021 | 1368 | 0.160 |
Why?
|
Estrone | 1 | 2020 | 232 | 0.160 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2019 | 4023 | 0.160 |
Why?
|
Contraceptives, Oral, Hormonal | 1 | 2020 | 190 | 0.160 |
Why?
|
Calcium | 4 | 2023 | 5721 | 0.160 |
Why?
|
Nuts | 1 | 2021 | 263 | 0.160 |
Why?
|
Low Back Pain | 2 | 2018 | 979 | 0.160 |
Why?
|
Fruit | 3 | 2015 | 1160 | 0.150 |
Why?
|
Preventive Medicine | 1 | 2020 | 247 | 0.150 |
Why?
|
Hand Strength | 2 | 2018 | 452 | 0.150 |
Why?
|
Developed Countries | 1 | 2021 | 440 | 0.150 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 7 | 2015 | 2269 | 0.150 |
Why?
|
Gallbladder Neoplasms | 1 | 2019 | 190 | 0.150 |
Why?
|
Deafness | 1 | 2022 | 457 | 0.150 |
Why?
|
Fibrinogen | 3 | 2018 | 883 | 0.150 |
Why?
|
Metabolism | 1 | 2019 | 193 | 0.150 |
Why?
|
Dry Eye Syndromes | 1 | 2022 | 385 | 0.150 |
Why?
|
Movement | 3 | 2019 | 1474 | 0.150 |
Why?
|
Apolipoprotein E4 | 1 | 2022 | 706 | 0.150 |
Why?
|
Cross-Sectional Studies | 15 | 2022 | 25956 | 0.140 |
Why?
|
Young Adult | 24 | 2022 | 58808 | 0.140 |
Why?
|
Universities | 6 | 2018 | 993 | 0.140 |
Why?
|
Activin Receptors, Type II | 1 | 2017 | 124 | 0.140 |
Why?
|
Gallbladder Diseases | 1 | 1998 | 137 | 0.140 |
Why?
|
Hypercholesterolemia | 2 | 2018 | 1138 | 0.140 |
Why?
|
Weather | 1 | 2018 | 226 | 0.140 |
Why?
|
DNA | 1 | 2010 | 7199 | 0.140 |
Why?
|
Reference Values | 3 | 2015 | 4919 | 0.140 |
Why?
|
Carcinoma, Small Cell | 1 | 2019 | 416 | 0.140 |
Why?
|
Exercise Therapy | 3 | 2021 | 919 | 0.130 |
Why?
|
Acetylgalactosamine | 1 | 2016 | 38 | 0.130 |
Why?
|
Muscle Weakness | 2 | 2018 | 413 | 0.130 |
Why?
|
Hormones | 1 | 2020 | 869 | 0.130 |
Why?
|
Atrial Fibrillation | 3 | 2022 | 5103 | 0.130 |
Why?
|
Platelet Aggregation Inhibitors | 4 | 2013 | 2747 | 0.130 |
Why?
|
Diuretics | 1 | 1999 | 610 | 0.130 |
Why?
|
Biological Evolution | 1 | 2021 | 1074 | 0.130 |
Why?
|
Exercise Test | 8 | 2020 | 2121 | 0.130 |
Why?
|
Lipids | 4 | 2019 | 3326 | 0.130 |
Why?
|
Lipoproteins | 3 | 2018 | 881 | 0.130 |
Why?
|
Reproduction | 1 | 2020 | 646 | 0.130 |
Why?
|
Monitoring, Ambulatory | 1 | 2019 | 352 | 0.130 |
Why?
|
Respiratory Tract Neoplasms | 1 | 1995 | 56 | 0.130 |
Why?
|
Methionine | 1 | 2018 | 569 | 0.130 |
Why?
|
Peer Group | 1 | 2020 | 677 | 0.120 |
Why?
|
Nonlinear Dynamics | 1 | 2017 | 493 | 0.120 |
Why?
|
Health Plan Implementation | 1 | 2018 | 336 | 0.120 |
Why?
|
Glass | 1 | 1995 | 115 | 0.120 |
Why?
|
Age Distribution | 5 | 2011 | 2882 | 0.120 |
Why?
|
Vitamin B Complex | 1 | 2017 | 297 | 0.120 |
Why?
|
Disability Evaluation | 2 | 2019 | 1825 | 0.120 |
Why?
|
Diabetic Nephropathies | 1 | 2022 | 973 | 0.120 |
Why?
|
Health | 1 | 1998 | 398 | 0.120 |
Why?
|
Linear Models | 5 | 2017 | 5862 | 0.120 |
Why?
|
Acetylglucosamine | 1 | 2016 | 189 | 0.120 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2019 | 419 | 0.120 |
Why?
|
Evidence-Based Practice | 1 | 2019 | 494 | 0.120 |
Why?
|
Activities of Daily Living | 2 | 2018 | 2414 | 0.120 |
Why?
|
Socioeconomic Factors | 7 | 2021 | 7818 | 0.120 |
Why?
|
Workplace | 1 | 2020 | 857 | 0.120 |
Why?
|
Interdisciplinary Communication | 1 | 2020 | 931 | 0.120 |
Why?
|
Respiratory Tract Infections | 1 | 2022 | 1005 | 0.110 |
Why?
|
Vitamin A | 1 | 2017 | 613 | 0.110 |
Why?
|
Habits | 1 | 2014 | 146 | 0.110 |
Why?
|
Brazil | 2 | 2015 | 1217 | 0.110 |
Why?
|
Receptor, Insulin | 1 | 2017 | 833 | 0.110 |
Why?
|
Estradiol | 2 | 2020 | 1933 | 0.110 |
Why?
|
Arthralgia | 1 | 2018 | 461 | 0.110 |
Why?
|
Accidental Falls | 2 | 2021 | 1056 | 0.110 |
Why?
|
Prognosis | 12 | 2023 | 29557 | 0.110 |
Why?
|
Carbon | 1 | 2017 | 667 | 0.110 |
Why?
|
Migraine Disorders | 4 | 2012 | 1694 | 0.110 |
Why?
|
Research | 2 | 2019 | 1976 | 0.110 |
Why?
|
Adolescent | 21 | 2022 | 87892 | 0.110 |
Why?
|
Death Certificates | 3 | 2021 | 167 | 0.110 |
Why?
|
Macular Degeneration | 1 | 2020 | 1001 | 0.110 |
Why?
|
Adenocarcinoma | 3 | 2021 | 6313 | 0.110 |
Why?
|
Testosterone | 4 | 2020 | 2471 | 0.110 |
Why?
|
Iron | 1 | 2021 | 1786 | 0.110 |
Why?
|
Bicycling | 1 | 2014 | 176 | 0.110 |
Why?
|
Cholesterol | 2 | 2020 | 2902 | 0.110 |
Why?
|
Transportation | 1 | 2014 | 214 | 0.100 |
Why?
|
Metabolome | 1 | 2019 | 982 | 0.100 |
Why?
|
Quantitative Trait Loci | 1 | 2021 | 2100 | 0.100 |
Why?
|
Oxygen Consumption | 2 | 2013 | 1845 | 0.100 |
Why?
|
Men's Health | 1 | 2012 | 73 | 0.100 |
Why?
|
Residence Characteristics | 3 | 2019 | 2058 | 0.100 |
Why?
|
Fatigue | 1 | 1999 | 1542 | 0.100 |
Why?
|
Mass Screening | 3 | 2020 | 5427 | 0.100 |
Why?
|
Microtubule-Associated Proteins | 1 | 2017 | 1074 | 0.100 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2010 | 10748 | 0.100 |
Why?
|
Life Tables | 1 | 2012 | 365 | 0.100 |
Why?
|
Patient Admission | 1 | 2019 | 1372 | 0.100 |
Why?
|
Diabetes, Gestational | 1 | 2022 | 1241 | 0.100 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2020 | 1704 | 0.100 |
Why?
|
Neoplasm Metastasis | 2 | 2020 | 4901 | 0.100 |
Why?
|
Predictive Value of Tests | 6 | 2017 | 15225 | 0.100 |
Why?
|
Heart Failure | 3 | 2022 | 11593 | 0.100 |
Why?
|
Occupational Diseases | 2 | 2020 | 1486 | 0.100 |
Why?
|
Depression | 2 | 2021 | 8057 | 0.090 |
Why?
|
Kidney Calculi | 1 | 2015 | 468 | 0.090 |
Why?
|
Asia | 3 | 2018 | 616 | 0.090 |
Why?
|
Osteoarthritis, Knee | 2 | 2020 | 1233 | 0.090 |
Why?
|
Telomere | 1 | 2017 | 931 | 0.090 |
Why?
|
Vegetables | 3 | 2015 | 1195 | 0.090 |
Why?
|
Premenopause | 4 | 2021 | 1038 | 0.090 |
Why?
|
Apolipoprotein A-I | 3 | 2020 | 294 | 0.090 |
Why?
|
Coffee | 1 | 2015 | 582 | 0.090 |
Why?
|
Internet | 2 | 2018 | 3082 | 0.090 |
Why?
|
Glaucoma | 1 | 2020 | 1182 | 0.090 |
Why?
|
Genotype | 6 | 2021 | 12945 | 0.090 |
Why?
|
Disabled Persons | 1 | 2020 | 1224 | 0.090 |
Why?
|
Physical Endurance | 1 | 2013 | 362 | 0.090 |
Why?
|
Lipoprotein Lipase | 1 | 2011 | 133 | 0.090 |
Why?
|
Survival Rate | 7 | 2020 | 12721 | 0.090 |
Why?
|
Fractures, Bone | 1 | 2022 | 2040 | 0.090 |
Why?
|
Cholesterol Ester Transfer Proteins | 1 | 2011 | 113 | 0.090 |
Why?
|
Comparative Effectiveness Research | 1 | 2015 | 715 | 0.090 |
Why?
|
Independent Living | 3 | 2019 | 567 | 0.090 |
Why?
|
Heart Diseases | 1 | 2022 | 2782 | 0.080 |
Why?
|
Receptors, Somatostatin | 1 | 2010 | 136 | 0.080 |
Why?
|
Autoimmune Diseases | 1 | 2022 | 2244 | 0.080 |
Why?
|
Disease Progression | 6 | 2020 | 13468 | 0.080 |
Why?
|
Program Evaluation | 1 | 2018 | 2492 | 0.080 |
Why?
|
Insulin-Like Growth Factor Binding Proteins | 1 | 2010 | 206 | 0.080 |
Why?
|
Treatment Failure | 3 | 2021 | 2640 | 0.080 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 2 | 2010 | 415 | 0.080 |
Why?
|
Analysis of Variance | 4 | 2020 | 6234 | 0.080 |
Why?
|
Body Height | 3 | 2015 | 1567 | 0.080 |
Why?
|
Homocysteine | 2 | 2010 | 638 | 0.080 |
Why?
|
Inflammation Mediators | 1 | 2018 | 1878 | 0.080 |
Why?
|
Population Density | 1 | 2009 | 192 | 0.080 |
Why?
|
Lipase | 1 | 2011 | 324 | 0.080 |
Why?
|
Blood Glucose | 6 | 2020 | 6346 | 0.080 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2021 | 8506 | 0.080 |
Why?
|
Rheumatoid Factor | 1 | 2008 | 185 | 0.080 |
Why?
|
Apolipoprotein B-100 | 2 | 2020 | 155 | 0.080 |
Why?
|
Peptide Fragments | 1 | 2020 | 5098 | 0.070 |
Why?
|
Intracranial Hemorrhages | 2 | 2011 | 820 | 0.070 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 3801 | 0.070 |
Why?
|
Dihydroxycholecalciferols | 1 | 2007 | 17 | 0.070 |
Why?
|
Muscles | 2 | 2023 | 1579 | 0.070 |
Why?
|
Body Fat Distribution | 1 | 2009 | 243 | 0.070 |
Why?
|
Multiple Myeloma | 2 | 2018 | 5129 | 0.070 |
Why?
|
Insulin-Like Growth Factor Binding Protein 2 | 1 | 2007 | 68 | 0.070 |
Why?
|
Europe | 3 | 2021 | 3420 | 0.070 |
Why?
|
Triglycerides | 3 | 2020 | 2451 | 0.070 |
Why?
|
Boston | 5 | 2020 | 9304 | 0.070 |
Why?
|
Registries | 2 | 2020 | 8175 | 0.070 |
Why?
|
Arthroplasty, Replacement, Knee | 1 | 2018 | 1370 | 0.070 |
Why?
|
Antigens, CD | 1 | 2017 | 3997 | 0.070 |
Why?
|
Dietary Fiber | 2 | 2015 | 759 | 0.070 |
Why?
|
Societies | 1 | 2007 | 108 | 0.070 |
Why?
|
Sleep | 2 | 2021 | 4744 | 0.070 |
Why?
|
Cyclooxygenase Inhibitors | 2 | 2005 | 361 | 0.070 |
Why?
|
Receptors, Calcitriol | 1 | 2009 | 359 | 0.070 |
Why?
|
Practice Guidelines as Topic | 2 | 2020 | 7378 | 0.070 |
Why?
|
Waist-Hip Ratio | 2 | 2019 | 516 | 0.070 |
Why?
|
Tryptophan | 2 | 2019 | 479 | 0.070 |
Why?
|
Parathyroid Hormone | 2 | 2023 | 1797 | 0.070 |
Why?
|
Recreation | 1 | 2006 | 119 | 0.070 |
Why?
|
Insulin-Secreting Cells | 1 | 2013 | 896 | 0.070 |
Why?
|
American Heart Association | 2 | 2007 | 1039 | 0.060 |
Why?
|
Fatty Acids | 2 | 2023 | 1803 | 0.060 |
Why?
|
Endpoint Determination | 1 | 2008 | 590 | 0.060 |
Why?
|
Sickness Impact Profile | 1 | 2007 | 298 | 0.060 |
Why?
|
Models, Statistical | 3 | 2019 | 5070 | 0.060 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2020 | 2420 | 0.060 |
Why?
|
Probability | 2 | 2001 | 2467 | 0.060 |
Why?
|
Sex Characteristics | 2 | 2022 | 2621 | 0.060 |
Why?
|
Neoplasm Invasiveness | 4 | 2019 | 3617 | 0.060 |
Why?
|
Acute-Phase Proteins | 2 | 2016 | 250 | 0.060 |
Why?
|
Cysteine | 1 | 2010 | 893 | 0.060 |
Why?
|
Causality | 3 | 2021 | 1241 | 0.060 |
Why?
|
Osteoporosis | 3 | 2022 | 1598 | 0.060 |
Why?
|
Morbidity | 2 | 2001 | 1754 | 0.060 |
Why?
|
Databases, Factual | 1 | 2000 | 7980 | 0.060 |
Why?
|
Sports Medicine | 1 | 2007 | 243 | 0.060 |
Why?
|
Glycemic Index | 2 | 2004 | 393 | 0.060 |
Why?
|
Regression Analysis | 5 | 2018 | 6354 | 0.060 |
Why?
|
Glucose Intolerance | 1 | 2008 | 575 | 0.060 |
Why?
|
Brain Ischemia | 3 | 2011 | 3047 | 0.060 |
Why?
|
Dementia | 1 | 2018 | 2650 | 0.060 |
Why?
|
Pneumonia | 1 | 2016 | 2129 | 0.060 |
Why?
|
Sweden | 2 | 2019 | 1376 | 0.060 |
Why?
|
Demography | 1 | 2009 | 1651 | 0.060 |
Why?
|
Biomedical Research | 1 | 2019 | 3418 | 0.060 |
Why?
|
Reproducibility of Results | 3 | 2016 | 20055 | 0.060 |
Why?
|
Gene Frequency | 1 | 2010 | 3612 | 0.060 |
Why?
|
Australia | 2 | 2018 | 1276 | 0.060 |
Why?
|
Drug Administration Schedule | 5 | 2016 | 4839 | 0.050 |
Why?
|
Research Design | 4 | 2017 | 6157 | 0.050 |
Why?
|
Comorbidity | 6 | 2020 | 10495 | 0.050 |
Why?
|
Magnesium | 1 | 2006 | 809 | 0.050 |
Why?
|
Genetic Variation | 2 | 2010 | 6548 | 0.050 |
Why?
|
Estrogen Replacement Therapy | 3 | 2007 | 1206 | 0.050 |
Why?
|
Alleles | 2 | 2011 | 6895 | 0.050 |
Why?
|
Area Under Curve | 2 | 2017 | 1632 | 0.050 |
Why?
|
Stria Vascularis | 1 | 2022 | 30 | 0.050 |
Why?
|
Nutrition Surveys | 3 | 2019 | 1716 | 0.050 |
Why?
|
Poultry | 1 | 2022 | 81 | 0.050 |
Why?
|
Treatment Outcome | 8 | 2022 | 64378 | 0.050 |
Why?
|
Healthcare Disparities | 1 | 2018 | 3364 | 0.050 |
Why?
|
Calcifediol | 1 | 2023 | 161 | 0.050 |
Why?
|
Epidemiologic Studies | 2 | 2007 | 670 | 0.050 |
Why?
|
Health Status Indicators | 1 | 2007 | 970 | 0.050 |
Why?
|
Cyclin T | 1 | 2021 | 19 | 0.050 |
Why?
|
Imipenem | 1 | 2021 | 37 | 0.050 |
Why?
|
Massachusetts | 4 | 2011 | 8823 | 0.050 |
Why?
|
Educational Status | 2 | 2003 | 2513 | 0.050 |
Why?
|
Carcinoma | 1 | 2012 | 2330 | 0.050 |
Why?
|
Recovery of Function | 1 | 2011 | 2970 | 0.050 |
Why?
|
Poisson Distribution | 2 | 2012 | 505 | 0.050 |
Why?
|
Social Medicine | 1 | 2001 | 64 | 0.050 |
Why?
|
Common Cold | 1 | 2001 | 63 | 0.050 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 3216 | 0.050 |
Why?
|
Hyperinsulinism | 1 | 2004 | 400 | 0.050 |
Why?
|
Golf | 1 | 2000 | 16 | 0.050 |
Why?
|
Head and Neck Neoplasms | 1 | 2015 | 2882 | 0.050 |
Why?
|
Quality of Life | 5 | 2021 | 13285 | 0.050 |
Why?
|
United States Social Security Administration | 1 | 2000 | 11 | 0.050 |
Why?
|
Dietary Fats | 2 | 2008 | 1991 | 0.050 |
Why?
|
Tennis | 1 | 2000 | 20 | 0.050 |
Why?
|
Drug Interactions | 1 | 2005 | 1414 | 0.050 |
Why?
|
Silicones | 1 | 2001 | 227 | 0.040 |
Why?
|
Lactams | 1 | 2021 | 154 | 0.040 |
Why?
|
Clinical Protocols | 2 | 2016 | 1436 | 0.040 |
Why?
|
Bile Ducts, Extrahepatic | 1 | 2019 | 49 | 0.040 |
Why?
|
Lipoproteins, VLDL | 1 | 2020 | 201 | 0.040 |
Why?
|
Drug Combinations | 2 | 2016 | 2020 | 0.040 |
Why?
|
Antibodies, Antinuclear | 1 | 2001 | 344 | 0.040 |
Why?
|
Neopterin | 1 | 2019 | 56 | 0.040 |
Why?
|
Smoking Cessation | 1 | 2011 | 2055 | 0.040 |
Why?
|
Child | 7 | 2021 | 79818 | 0.040 |
Why?
|
Pyridoxic Acid | 1 | 2019 | 4 | 0.040 |
Why?
|
Masks | 1 | 2022 | 207 | 0.040 |
Why?
|
Pensions | 1 | 2019 | 15 | 0.040 |
Why?
|
Estrogen Receptor beta | 1 | 2020 | 168 | 0.040 |
Why?
|
Receptors, Progesterone | 3 | 2010 | 1130 | 0.040 |
Why?
|
Data Collection | 2 | 2016 | 3322 | 0.040 |
Why?
|
Common Bile Duct Neoplasms | 1 | 2019 | 120 | 0.040 |
Why?
|
Health Personnel | 5 | 2014 | 3312 | 0.040 |
Why?
|
Fallopian Tubes | 1 | 2020 | 178 | 0.040 |
Why?
|
Ampulla of Vater | 1 | 2019 | 149 | 0.040 |
Why?
|
Leucine | 1 | 2020 | 547 | 0.040 |
Why?
|
History, 20th Century | 2 | 2010 | 2772 | 0.040 |
Why?
|
Bile Ducts | 1 | 2020 | 282 | 0.040 |
Why?
|
beta-Lactamases | 1 | 2021 | 304 | 0.040 |
Why?
|
Cities | 1 | 2021 | 541 | 0.040 |
Why?
|
Administration, Oral | 1 | 2006 | 3991 | 0.040 |
Why?
|
Retrospective Studies | 11 | 2018 | 80168 | 0.040 |
Why?
|
Validation Studies as Topic | 1 | 2019 | 162 | 0.040 |
Why?
|
Contraceptive Agents | 1 | 2020 | 145 | 0.040 |
Why?
|
Epidemiologic Methods | 1 | 2003 | 1338 | 0.040 |
Why?
|
Apolipoproteins | 1 | 2020 | 319 | 0.040 |
Why?
|
Cholangitis, Sclerosing | 1 | 2020 | 177 | 0.040 |
Why?
|
International Agencies | 1 | 2019 | 243 | 0.040 |
Why?
|
Femur Neck | 1 | 2020 | 312 | 0.040 |
Why?
|
Hepatocyte Nuclear Factor 1-beta | 1 | 2018 | 92 | 0.040 |
Why?
|
Patient Participation | 1 | 2007 | 1436 | 0.040 |
Why?
|
Ischemia | 1 | 2006 | 1863 | 0.040 |
Why?
|
General Practice | 1 | 2018 | 96 | 0.040 |
Why?
|
Hepatocyte Nuclear Factor 4 | 1 | 2018 | 126 | 0.040 |
Why?
|
Pain Measurement | 2 | 2018 | 3527 | 0.040 |
Why?
|
Lipoproteins, LDL | 1 | 2020 | 640 | 0.040 |
Why?
|
Molecular Epidemiology | 1 | 2019 | 469 | 0.040 |
Why?
|
Pancreatitis, Chronic | 1 | 2020 | 281 | 0.040 |
Why?
|
Tokyo | 1 | 2016 | 25 | 0.040 |
Why?
|
Carrier Proteins | 1 | 2010 | 4938 | 0.040 |
Why?
|
Publications | 1 | 2019 | 194 | 0.040 |
Why?
|
Government | 1 | 2018 | 161 | 0.040 |
Why?
|
Texas | 2 | 2008 | 402 | 0.040 |
Why?
|
Self Disclosure | 1 | 1998 | 249 | 0.040 |
Why?
|
Organizational Culture | 1 | 2020 | 506 | 0.030 |
Why?
|
Asthma | 1 | 2016 | 6172 | 0.030 |
Why?
|
Ontario | 1 | 2018 | 397 | 0.030 |
Why?
|
Maternal Age | 1 | 2019 | 807 | 0.030 |
Why?
|
Single-Blind Method | 1 | 2020 | 1570 | 0.030 |
Why?
|
Women's Health Services | 1 | 2017 | 89 | 0.030 |
Why?
|
Linkage Disequilibrium | 1 | 2021 | 1996 | 0.030 |
Why?
|
Pennsylvania | 1 | 1998 | 614 | 0.030 |
Why?
|
Animals | 7 | 2022 | 167768 | 0.030 |
Why?
|
Feeding Behavior | 2 | 2010 | 3184 | 0.030 |
Why?
|
Somatotypes | 1 | 1996 | 41 | 0.030 |
Why?
|
Lipoproteins, HDL | 1 | 2020 | 664 | 0.030 |
Why?
|
Efficiency, Organizational | 1 | 2020 | 696 | 0.030 |
Why?
|
Physical Education and Training | 1 | 1996 | 100 | 0.030 |
Why?
|
Estrogen Receptor alpha | 1 | 2020 | 580 | 0.030 |
Why?
|
Myocardial Revascularization | 1 | 2020 | 792 | 0.030 |
Why?
|
Lipoprotein(a) | 1 | 2020 | 479 | 0.030 |
Why?
|
Cochlea | 1 | 2022 | 844 | 0.030 |
Why?
|
Pliability | 1 | 2015 | 58 | 0.030 |
Why?
|
Capacity Building | 1 | 2018 | 257 | 0.030 |
Why?
|
Counseling | 2 | 2020 | 1541 | 0.030 |
Why?
|
European Union | 1 | 2016 | 157 | 0.030 |
Why?
|
Quality-Adjusted Life Years | 2 | 2015 | 1722 | 0.030 |
Why?
|
Placebos | 2 | 2012 | 1661 | 0.030 |
Why?
|
Tobacco Smoke Pollution | 1 | 2001 | 812 | 0.030 |
Why?
|
Netherlands | 1 | 2020 | 2212 | 0.030 |
Why?
|
Chi-Square Distribution | 2 | 2017 | 3425 | 0.030 |
Why?
|
Sensitivity and Specificity | 4 | 2019 | 14641 | 0.030 |
Why?
|
Introns | 1 | 2017 | 978 | 0.030 |
Why?
|
Adenocarcinoma, Clear Cell | 1 | 2016 | 217 | 0.030 |
Why?
|
Biological Specimen Banks | 1 | 2020 | 782 | 0.030 |
Why?
|
Health Services for the Aged | 1 | 2017 | 259 | 0.030 |
Why?
|
Glucose Tolerance Test | 1 | 2017 | 1172 | 0.030 |
Why?
|
Microbial Sensitivity Tests | 1 | 2021 | 1945 | 0.030 |
Why?
|
Hysterectomy | 1 | 2020 | 904 | 0.030 |
Why?
|
Drinking | 1 | 2015 | 199 | 0.030 |
Why?
|
Nutritional Physiological Phenomena | 1 | 1996 | 362 | 0.030 |
Why?
|
Glomerular Filtration Rate | 1 | 2022 | 2154 | 0.030 |
Why?
|
Hip Fractures | 1 | 2022 | 987 | 0.030 |
Why?
|
Heart Rate | 2 | 2019 | 4166 | 0.030 |
Why?
|
Students | 3 | 1992 | 1734 | 0.030 |
Why?
|
Absorptiometry, Photon | 1 | 2020 | 1735 | 0.030 |
Why?
|
Seasons | 1 | 2019 | 1519 | 0.030 |
Why?
|
Carcinoma, Endometrioid | 1 | 2016 | 276 | 0.030 |
Why?
|
Laboratories | 1 | 2017 | 460 | 0.030 |
Why?
|
Clinical Trials as Topic | 2 | 2022 | 7985 | 0.030 |
Why?
|
Proinsulin | 1 | 2013 | 135 | 0.030 |
Why?
|
Self Efficacy | 1 | 2017 | 632 | 0.030 |
Why?
|
Nuclear Magnetic Resonance, Biomolecular | 1 | 2016 | 509 | 0.030 |
Why?
|
Cognition | 2 | 2022 | 6953 | 0.030 |
Why?
|
North America | 1 | 2016 | 1276 | 0.030 |
Why?
|
Genetic Markers | 1 | 2019 | 2608 | 0.030 |
Why?
|
Death, Sudden, Cardiac | 1 | 2000 | 1554 | 0.030 |
Why?
|
Self Medication | 2 | 2006 | 117 | 0.030 |
Why?
|
Celiac Disease | 1 | 2020 | 822 | 0.030 |
Why?
|
Consensus | 2 | 2015 | 3099 | 0.030 |
Why?
|
Adenocarcinoma, Mucinous | 1 | 2016 | 517 | 0.020 |
Why?
|
Survival Analysis | 2 | 2020 | 10112 | 0.020 |
Why?
|
Family Characteristics | 1 | 2017 | 1000 | 0.020 |
Why?
|
Colonoscopy | 1 | 2020 | 1388 | 0.020 |
Why?
|
Cystadenocarcinoma, Serous | 1 | 2016 | 479 | 0.020 |
Why?
|
Bibliometrics | 1 | 2015 | 349 | 0.020 |
Why?
|
Caenorhabditis elegans | 1 | 2021 | 1444 | 0.020 |
Why?
|
Insulin | 2 | 2019 | 6578 | 0.020 |
Why?
|
Forecasting | 1 | 2020 | 2923 | 0.020 |
Why?
|
Meta-Analysis as Topic | 1 | 2016 | 1373 | 0.020 |
Why?
|
Health Education | 1 | 2017 | 1049 | 0.020 |
Why?
|
Databases, Genetic | 1 | 2018 | 1737 | 0.020 |
Why?
|
ROC Curve | 1 | 2018 | 3563 | 0.020 |
Why?
|
Social Support | 2 | 2016 | 2155 | 0.020 |
Why?
|
Caffeine | 1 | 2015 | 701 | 0.020 |
Why?
|
Blood Proteins | 1 | 2016 | 1173 | 0.020 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2018 | 1651 | 0.020 |
Why?
|
Prevalence | 3 | 2016 | 15651 | 0.020 |
Why?
|
Estradiol Dehydrogenases | 1 | 2010 | 15 | 0.020 |
Why?
|
Congresses as Topic | 1 | 2015 | 799 | 0.020 |
Why?
|
Chemoprevention | 1 | 2012 | 326 | 0.020 |
Why?
|
Diabetes Complications | 1 | 2017 | 1317 | 0.020 |
Why?
|
Personality | 1 | 1994 | 552 | 0.020 |
Why?
|
Athletes | 1 | 1998 | 1125 | 0.020 |
Why?
|
Pyridoxal Phosphate | 1 | 2010 | 124 | 0.020 |
Why?
|
Mammography | 1 | 2001 | 2427 | 0.020 |
Why?
|
Risk-Taking | 1 | 1996 | 1034 | 0.020 |
Why?
|
Phenotype | 2 | 2017 | 16534 | 0.020 |
Why?
|
Receptors, Steroid | 1 | 2010 | 155 | 0.020 |
Why?
|
Leukocytes | 1 | 2017 | 2025 | 0.020 |
Why?
|
Income | 1 | 2018 | 1872 | 0.020 |
Why?
|
Cost-Benefit Analysis | 2 | 2015 | 5484 | 0.020 |
Why?
|
Truth Disclosure | 1 | 1993 | 432 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 2017 | 1840 | 0.020 |
Why?
|
Pregnancy | 2 | 2022 | 29742 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2015 | 2697 | 0.020 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2021 | 2276 | 0.020 |
Why?
|
Colitis, Ulcerative | 1 | 2020 | 1919 | 0.020 |
Why?
|
Recurrence | 1 | 2020 | 8426 | 0.020 |
Why?
|
Mycosis Fungoides | 1 | 1989 | 168 | 0.020 |
Why?
|
Hypoglycemic Agents | 1 | 2020 | 3069 | 0.020 |
Why?
|
Drug Therapy, Combination | 2 | 2012 | 6293 | 0.020 |
Why?
|
Genetic Loci | 1 | 2017 | 2612 | 0.020 |
Why?
|
Androstenedione | 1 | 2007 | 131 | 0.020 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2018 | 2872 | 0.020 |
Why?
|
Crohn Disease | 1 | 2020 | 2275 | 0.020 |
Why?
|
Bacterial Proteins | 1 | 2021 | 3824 | 0.020 |
Why?
|
Cocarcinogenesis | 1 | 2007 | 49 | 0.020 |
Why?
|
Cerebral Hemorrhage | 1 | 1999 | 2650 | 0.020 |
Why?
|
Thinness | 1 | 2010 | 490 | 0.020 |
Why?
|
Genetic Association Studies | 1 | 2016 | 2717 | 0.020 |
Why?
|
Repressor Proteins | 1 | 2018 | 2980 | 0.020 |
Why?
|
Psychometrics | 1 | 2016 | 3052 | 0.020 |
Why?
|
Bone Density | 1 | 2020 | 3533 | 0.020 |
Why?
|
Dehydroepiandrosterone | 1 | 2007 | 257 | 0.020 |
Why?
|
Social Class | 1 | 2015 | 1999 | 0.020 |
Why?
|
Societies, Scientific | 1 | 2007 | 220 | 0.020 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2013 | 1110 | 0.020 |
Why?
|
Pain | 1 | 2021 | 5065 | 0.020 |
Why?
|
Neoplasm Staging | 2 | 2015 | 11152 | 0.020 |
Why?
|
Health Policy | 1 | 2018 | 2677 | 0.020 |
Why?
|
Patient Readmission | 1 | 2019 | 3261 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2016 | 6493 | 0.020 |
Why?
|
Lung | 2 | 2016 | 9985 | 0.020 |
Why?
|
Respiratory System | 1 | 2008 | 557 | 0.020 |
Why?
|
Markov Chains | 1 | 2008 | 965 | 0.020 |
Why?
|
Estrogens | 2 | 2004 | 1520 | 0.020 |
Why?
|
Acute Disease | 1 | 2016 | 7225 | 0.020 |
Why?
|
Mice | 2 | 2022 | 81101 | 0.010 |
Why?
|
Selection Bias | 1 | 2006 | 357 | 0.010 |
Why?
|
History, 21st Century | 1 | 2010 | 1573 | 0.010 |
Why?
|
Evidence-Based Medicine | 1 | 2016 | 3671 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2021 | 7843 | 0.010 |
Why?
|
Patient Selection | 1 | 2016 | 4244 | 0.010 |
Why?
|
Haplotypes | 1 | 2010 | 2764 | 0.010 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2018 | 3992 | 0.010 |
Why?
|
Receptors, Androgen | 1 | 2009 | 1077 | 0.010 |
Why?
|
Diet Surveys | 1 | 2007 | 1161 | 0.010 |
Why?
|
Cerebral Arteries | 1 | 2005 | 492 | 0.010 |
Why?
|
Suicide | 1 | 1994 | 1599 | 0.010 |
Why?
|
Melanoma | 1 | 2021 | 5691 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2021 | 7403 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2013 | 4342 | 0.010 |
Why?
|
Hyperlipidemias | 1 | 2006 | 772 | 0.010 |
Why?
|
DNA Topoisomerases, Type I | 1 | 2001 | 105 | 0.010 |
Why?
|
Angioplasty, Balloon, Coronary | 1 | 2008 | 1730 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2010 | 6068 | 0.010 |
Why?
|
Autoimmunity | 1 | 2009 | 1358 | 0.010 |
Why?
|
Complement C4 | 1 | 2001 | 244 | 0.010 |
Why?
|
Age of Onset | 1 | 2007 | 3298 | 0.010 |
Why?
|
Creatinine | 1 | 2006 | 1892 | 0.010 |
Why?
|
Seroepidemiologic Studies | 1 | 2001 | 394 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2018 | 15785 | 0.010 |
Why?
|
Homeodomain Proteins | 1 | 2009 | 2413 | 0.010 |
Why?
|
DNA, Single-Stranded | 1 | 2001 | 352 | 0.010 |
Why?
|
Complement C3 | 1 | 2001 | 451 | 0.010 |
Why?
|
Coronary Artery Bypass | 1 | 2008 | 2189 | 0.010 |
Why?
|
Polymorphism, Genetic | 1 | 2009 | 4284 | 0.010 |
Why?
|
Respiratory Function Tests | 1 | 2003 | 1680 | 0.010 |
Why?
|
Immunoglobulin A | 1 | 2001 | 979 | 0.010 |
Why?
|
Physical Examination | 1 | 2003 | 1245 | 0.010 |
Why?
|
Random Allocation | 1 | 2001 | 2385 | 0.010 |
Why?
|
Family Health | 1 | 2001 | 1257 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2002 | 2850 | 0.010 |
Why?
|
Immunoglobulin M | 1 | 2001 | 1529 | 0.010 |
Why?
|
Pilot Projects | 1 | 2009 | 8553 | 0.010 |
Why?
|
Heart | 1 | 2008 | 4382 | 0.010 |
Why?
|
Health Care Costs | 1 | 2008 | 3245 | 0.010 |
Why?
|
Electrocardiography | 1 | 2008 | 6363 | 0.010 |
Why?
|
Behavior Therapy | 1 | 2001 | 869 | 0.010 |
Why?
|
Medical Records | 1 | 1999 | 1406 | 0.010 |
Why?
|
Connecticut | 1 | 1994 | 365 | 0.010 |
Why?
|
Coronary Artery Disease | 1 | 2011 | 6362 | 0.010 |
Why?
|
Personality Inventory | 1 | 1994 | 1018 | 0.010 |
Why?
|
Skin Neoplasms | 1 | 1989 | 5797 | 0.010 |
Why?
|
Immunoglobulin G | 1 | 2001 | 4540 | 0.010 |
Why?
|
Signal Transduction | 1 | 2010 | 23342 | 0.000 |
Why?
|
Occupations | 1 | 1989 | 515 | 0.000 |
Why?
|
Nuclear Proteins | 1 | 2001 | 5786 | 0.000 |
Why?
|
Antibodies, Monoclonal | 1 | 2001 | 9160 | 0.000 |
Why?
|
Hypersensitivity | 1 | 1989 | 1155 | 0.000 |
Why?
|
Brain | 1 | 2005 | 26947 | 0.000 |
Why?
|
Environmental Exposure | 1 | 1989 | 4412 | 0.000 |
Why?
|